Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid
Clandinin MT, Van Aerde JE, Merkel KL, Harris CL, Springer MA, Hansen JW, Diersen-Schade DA
The Journal of pediatrics · 151 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2005-04-01 · J Pediatr · vol. 146 · número 4 · págs. 461–468
- Editorial
- Elsevier BV
- Citado
- 247 citas · más que el 99% de estudios similares · 16.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 30 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Infant Nutrition and Health · Infant Development and Preterm Care
- Palabras clave
- preterm infants, infant formula, docosahexaenoic acid, arachidonic acid, algal oil, fish oil, fungal oil, omega-3 supplementation, infant growth, brain development, Bayley scores, long-term follow-up
- MeSH
- humans, docosahexaenoic acids, arachidonic acid, follow-up studies, prospective studies, double-blind method, infant formula, infant, newborn, infant, premature, female, male
7 autores
- Michael Thomas Clandinin🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- John E. Van Aerde🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- Kimberly L. Merkel🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- Cheryl L. Harris🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- Mary Alice Springer🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- James W. Hansen🇨🇦🇺🇸University of Alberta; Mead Johnson (United States)
- Deborah A. Diersen-Schade🇨🇦🇺🇸 · autor de correspondenciaUniversity of Alberta; Mead Johnson (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To evaluate safety and benefits of feeding preterm infants formulas containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) until 92 weeks postmenstrual age (PMA), with follow-up to 118 weeks PMA.
Study design
This double-blinded study of 361 preterm infants randomized across three formula groups: (1) control, no supplementation; (2) algal-DHA (DHA from algal oil, ARA from fungal oil); and (3) fish-DHA (DHA from fish oil, ARA from fungal oil). Term infants breast-fed > or =4 months (n = 105) were a reference group. Outcomes included growth, tolerance, adverse events, and Bayley development scores.
Results
Weight of the algal-DHA group was significantly greater than the control group from 66 to 118 weeks PMA and the fish-DHA group at 118 weeks PMA but did not differ from term infants at 118 weeks PMA. The algal-DHA group was significantly longer than the control group at 48, 79, and 92 weeks PMA and the fish-DHA group at 57, 79, and 92 weeks PMA but did not differ from term infants from 79 to 118 weeks PMA. Supplemented groups had higher Bayley mental and psychomotor development scores at 118 weeks PMA than did the control group. Supplementation did not increase morbidity or adverse events.
Conclusions
Feeding formulas with DHA and ARA from algal and fungal oils resulted in enhanced growth. Both supplemented formulas provided better developmental outcomes than unsupplemented formulas.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.